Cas:918650-88-1 9-naphthalen-2-yl-3-azaspiro[5.5]undec-9-ene manufacturer & supplier

Chemical Name:9-naphthalen-2-yl-3-azaspiro[5.5]undec-9-ene

CAS.NO:918650-88-1

Synonyms:3-Azaspiro[5.5]undec-8-ene,9-(2-naphthalenyl)

Molecular Formula:C₂₀H₂₃N

Molecular Weight:277.40300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:12.03000

Exact Mass:277.18300

LogP:5.10570

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Azaspiro[5.5]undec-8-ene,9-(2-naphthalenyl) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Azaspiro[5.5]undec-8-ene,9-(2-naphthalenyl) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Azaspiro[5.5]undec-8-ene,9-(2-naphthalenyl) Use and application,3-Azaspiro[5.5]undec-8-ene,9-(2-naphthalenyl) technical grade,usp/ep/jp grade.

Related News: US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. 9-naphthalen-2-yl-3-azaspiro[5.5]undec-9-ene manufacturer US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. 9-naphthalen-2-yl-3-azaspiro[5.5]undec-9-ene supplier Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,�� Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement. 9-naphthalen-2-yl-3-azaspiro[5.5]undec-9-ene vendor US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. 9-naphthalen-2-yl-3-azaspiro[5.5]undec-9-ene factory Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma.